Bolt Biotherapeutics (BOLT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.35 (+0.15%), Market cap $0.01B, 52-week low–high $0.30 ~ $7.09.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1
Financial statements, price targets, institutional (13F) holdings and related news for Bolt Biotherapeutics are updated in real time on BlackAll Trade.
Bolt Biotherapeutics trades at $3.35 (+0.15%). Real-time quotes and charts are available on BlackAll Trade.
Bolt Biotherapeutics has a market cap of about $0.01B.
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation